The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations

Psychiatry Research

Volumn 229, Issue 3, 2015, Pages 760-770

  Mohamed, Somaia ^a,o   Johnson, Gary R ^a   Vertrees, Julia E ^b   Guarino, Peter D ^a,c   Weingart, Kimberly ^d   Young, Ilanit Tal ^d   Yoon, Jean ^e   Gleason, Theresa C ^f   Kirkwood, Katherine A ^a   Kilbourne, Amy M ^f,g   Gerrity, Martha ^h   Marder, Stephen ⁱ   Biswas, Kousick ^j   Hicks, Paul ^k   Davis, Lori L ^l,n   Chen, Peijun ^m   Kelada, AlexandraMary ^d   Huang, Grant D ^f   Lawrence, David D ^a   LeGwin, Mary ^a   Zisook, Sidney ^d   more..

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b University of New Mexico   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Health Economics Resource Center   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h VA Portland Health Care System   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j VA Maryland Healthcare Center   (United States)

^k TEXAS A M COLLEGE OF MEDICINE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^o YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Antidepressants; Antipsychotics; Major depression; Methodology; Study design; Treatment resistance

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; MIRTAZAPINE; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADVERSE OUTCOME; AKATHISIA; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION; DRUG SUBSTITUTION; FEMALE; MALE; METHODOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; REMISSION INDUCTION; RESEARCH DESIGN; TIME FACTORS;

EID: 84941259710     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.08.005     Document Type: Article

References (68)

1. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl. 7):S22-S31.
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
3. American Psychiatric Association Practice guidelines for the psychiatric evaluation of adults 2006, American Psychiatric Association, Arlington, VA. 2nd ed.
4. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Bauer M.S., Williford W.O., Dawson E.E., Akiskal H.S., Altshuler L., Fye C., Gelenberg A., Glick H., Kinosian B., Sajatovic M. Principles of effectiveness trials and their implementation in VA Cooperative Study #430:''Reducing the efficacy-effectiveness gap in bipolar disorder'. Journal of affective disorders 2001, 67:61-78.
6. Bech P., Fava M., Trivedi M.H., Wisniewski S.R., Rush A.J. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr. Scand. 2012, 125:342-348.
7. Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 1988, 56:893-897.
8. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 2007, 68:843-853.
9. Bernstein D.P., Stein J.A., Newcomb M.D., Walker E., Pogge D., Ahluvalia T., Stokes J., Handelsman L., Medrano M., Desmond D., Zule W. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abus. Negl. 2003, 27:169-190.
10. Cabana M.D., Rushton J.L., Rush A.J. Implementing practice guidelines for depression: applying a new framework to an old problem. Gen. Hosp. Psychiatry 2002, 24:35-42.
11. Clayton A.H., Warnock J.K., Kornstein S.G., Pinkerton R., Sheldon-Keller A., McGarvey E.L. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. The Journal of clinical psychiatry 2004, 65:62-67.
12. Crismon M.L., Trivedi M., Pigott T.A., Rush A.J., Hirschfeld R.M., Kahn D.A., DeBattista C., Nelson J.C., Nierenberg A.A., Sackeim H.A., Thase M.E. The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J. Clin. Psychiatry 1999, 60:142-156.
13. DeBattista C., Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009, 23:369-377.
14. Depp C., Lebowitz B.D. Clinical trials: bridging the gap between efficacy and effectiveness. Int. Rev. Psychiatry 2007, 19:531-539.
15. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 1993, 29:321-326.
16. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J. Am. Med. Assoc. 2010, 303:47-53.
17. Guy W. ECDEU assessment manual for psychopharmacology-revised. U.S. Department of Health, Education, and Welfare. Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration 1976, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
18. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
19. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
20. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet 2012, 380:2053-2054.
21. Iovieno N., Papakostas G.I. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?. J. Clin. Psychiatry 2012, 73:676-683.
22. Judd L.L., Akiskal H.S., Paulus M.P. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J. Affect. Disord. 1997, 45:5-17. (discussion 17-18).
23. Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., Maser J.D., Mueller T., Solomon D.A., Keller M.B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am. J. Psychiatry 2000, 157:1501-1504.
24. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
25. Kennedy S.H., Lam R.W., Parikh S.V., Patten S.B., Ravindran A.V. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J. Affect. Disord. 2009, 117(Suppl 1):S1-S2.
26. Kraus T., Haack M., Schuld A., Hinze-Selch D., Kuhn M., Uhr M., Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 1999, 156:312-314.
27. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 2001, 16:606-613.
28. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
29. Leslie D.L., Mohamed S., Rosenheck R.A. Off-label use of antipsychotic medications in the department of veterans affairs health care system. Psychiatr. Serv. 2009, 60:1175-1181.
30. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale. J. Am. Geriatr. Soc. 1968, 16:622-626.
31. Mann H. Deception in the single-blind run-in phase of clinical trials. IRB 2007, 29:14-17.
32. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2008, 28:156-165.
33. McGahuey, C.A., Gelenberg, A.J., 1997. The Arizona Sexual Experience Scale: validity and reliability. In: New Research Program and Abstracts. 150th Annual Meeting of the American Psychiatric Association. APA, Washington, DC.
34. Miller I.W., Keitner G.I., Schatzberg A.F., Klein D.N., Thase M.E., Rush A.J., Markowitz J.C., Schlager D.S., Kornstein S.G., Davis S.M., Harrison W.M., Keller M.B. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 1998, 59:608-619.
35. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., Mulsant B., Reynolds C.F. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992, 41:237-248.
36. Mohamed S., Leslie D.L., Rosenheck R.A. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. J. Clin. Psychiatry 2009, 70:906-912.
37. Mundt J.C., Marks I.M., Shear M.K., Greist J.H. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br. J. Psychiatry: J. Ment. Sci. 2002, 180:461-464.
38. Murphy J.M., Monson R.R., Olivier D.C., Sobol A.M., Leighton A.H. Affective disorders and mortality. A general population study. Arch. Gen. Psychiatry 1987, 44:473-480.
39. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):S1-S93.
40. Newcomer J.W. Metabolic syndrome and mental illness. Am. J. Manag. Care 2007, 13:S170-S177.
41. Papakostas G.I., Trivedi M.H., Alpert J.E., Seifert C.A., Krishen A., Goodale E.P., Tucker V.L. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J. Psychiatr. Res. 2008, 42:134-140.
42. Posner K., Melvin G.A., Stanley B., Oquendo M.A., Gould M. Factors in the assessment of suicidality in youth. CNS Spectr. 2007, 12:156-162.
43. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
44. Quitkin F.M., McGrath P.J., Stewart J.W., Ocepek-Welikson K., Taylor B.P., Nunes E., Deliyannides D., Agosti V., Donovan S.J., Petkova E., Klein D.F. Chronological milestones to guide drug change. When should clinicians switch antidepressants?. Arch. Gen. Psychiatry 1996, 53:785-792.
45. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4:353-365.
46. Rush A.J. STAR*D: what have we learned?. AmJ. Psychiatry 2007, 164:201-204.
47. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., Markowitz J.C., Ninan P.T., Kornstein S., Manber R., Thase M.E., Kocsis J.H., Keller M.B. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 2003, 54:573-583.
48. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AmJ. Psychiatry 2006, 163:1905-1917.
49. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M., Team S.D.S. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:1231-1242.
50. Rush A.J., Warden D., Wisniewski S.R., Fava M., Trivedi M.H., Gaynes B.N., Nierenberg A.A. STAR*D: revising conventional wisdom. CNS Drugs 2009, 23:627-647.
51. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 2001, 62(Suppl. 16):S10-S17.
52. Sapin C., Fantino B., Nowicki M.L., Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2004, 2:20.
53. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):S22-S33. (quiz 34-57).
54. Swainston Harrison T.S., Perry C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64:1715-1735.
55. Thase M.E. Achieving remission and managing relapse in depression. J. Clin. Psychiatry 2003, 64(Suppl. 18):S3-S7.
56. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., VanMeter S., Harriett A.E., Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J. Clin. Psychiatry 2005, 66:974-981.
57. The Management of MDD Working Group, 2009. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (MDD). Department of Defense and Department of Veterans Affairs, Washington, DC.
58. Trivedi M.H. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J. Clin. Psychiatry 2009, 70(Suppl. 6):S26-S31.
59. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., Ritz L., Nierenberg A.A., Lebowitz B.D., Biggs M.M., Luther J.F., Shores-Wilson K., Rush A.J., Team S.D.S. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:S1243-S1252.
60. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
61. Trivedi M.H., Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. Neuropsychopharmacology 1994, 11:33-43.
62. Tunis S.R., Stryer D.B., Clancy C.M. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. J. Am. Med. Assoc. 2003, 290:1624-1632.
63. Wang P.S., Ulbricht C.M., Schoenbaum M. Improving mental health treatments through comparative effectiveness research. Health Aff. 2009, 28:783-791.
64. Weathers, F.W., Litz, B.T., Keane, T.M., Palmieri, P.A., Marx, B.P., Schnurr, P.P., 2013. The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at . http://www.ptsd.va.gov.
65. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 1998, 44:778-783.
66. Wisniewski S.R., Rush A.J., Balasubramani G.K., Trivedi M.H., Nierenberg A.A., Investigators S. Self-rated global measure of the frequency, intensity, and burden of side effects. J. Psychiatric Pract. 2006, 12:71-79.
67. Yager J., Kunkle R., Fochtmann L.J., Reid S.M., Plovnick R., Nininger J.E., Silverman J.J., Vergare M.J. Who's your expert? Use of an expert opinion survey to inform development of American Psychiatric Association practice guidelines. Acad. Psychiatry 2014, 38:376-382.
68. Zisook S., Rush A.J., Haight B.R., Clines D.C., Rockett C.B. Use of bupropion in combination with serotonin reuptake inhibitors. Biol. Psychiatry 2006, 59:203-210.